Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome caused by genetic defects in cytotoxic lymphocyte function. Current therapies can control disease activity, but transplantation of allogeneic hematopoietic stem and progenitor cells (HSPCs) remains the only curative option and is associated with substantial risks. These limitations have accelerated development of genome editing approaches enabling precise correction of disease-causing mutations in autologous cells. Familial HLH (FHL) represents a compelling target for genome editing, but successful and safe clinical translation has remained challenging. Preclinical studies demonstrate that targeted editing of key genes, such as PRF1 and UNC13D, can restore cytotoxic function in HSPCs and T cells. Translation to the clinic, however, depends on multiple factors, including the choice of target cell population, the level of functional correction required, and gene-specific constraints such as locus complexity and regulation of gene expression. In this review, we synthesize current progress in genome editing for FHL and highlight critical biological and technical barriers to clinical implementation. We propose a conceptual framework for designing genome editing strategies tailored to FHL, emphasizing the alignment of editing platform, gene architecture, and cellular context to enable effective and clinically translatable therapies.
ParikhSA, KapoorP, LetendreL, et al.Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc2014;89(4):484–492.
2.
WuY, SunX, KangK, et al.Hemophagocytic lymphohistiocytosis: Current treatment advances, emerging targeted therapy and underlying mechanisms. J Hematol Oncol2024;17(1):106.
3.
YangY, TuS, PengH, et al.Promising targeted therapies for hemophagocytic lymphohistiocytosis: A translational perspective based on immunopathology. Clin Rev Allergy Immunol2025;68(1):56.
4.
JordanMB. Hemophagocytic lymphohistiocytosis: A disorder of T cell activation, immune regulation, and distinctive immunopathology. Immunol Rev2024;322(1):339–350.
5.
ToumehN, Abu-ZeinahKF, GodbyRC. Hemophagocytic lymphohistiocytosis (HLH): A narrative review of the pathogenesis, clinical presentation, diagnosis, treatment, and prognosis. Ann Blood2025;10(1):8.
6.
LyuX, WeiP, ZhuLB, et al.Neonatal-onset familial hemophagocytic lymphohistiocytosis: A case report with genetic confirmation of PRF1 mutations. Front Genet2025;16:1690283.
7.
Brik SimonD, Greental NessY, DganyO, et al.A nationwide analysis of the phenotype/genotype landscape of hemophagocytic lymphohistiocytosis: UNC13D associates with poor prognosis. Genes (Basel)2025;16(11):1315.
8.
AmmannS, SchulzA, Krägeloh-MannI, et al.Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome. Blood2016;127(8):997–1006.
9.
VoskoboinikI, WhisstockJC, TrapaniJA. Perforin and granzymes: Function, dysfunction and human pathology. Nat Rev Immunol2015;15(6):388–400.
10.
StinchcombeJC, GriffithsGM. Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol2007;23(1):495–517.
11.
de Saint BasileG, MénaschéG, FischerA. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol2010;10(8):568–579.
12.
JankaGE, LehmbergK. Hemophagocytic lymphohistiocytosis: Pathogenesis and treatment. Hematology Am Soc Hematol Educ Program2013;2013(1):605–611.
13.
JankaGE. History of Hemophagocytic Lymphohistiocytosis. In: CronRQ, BehrensEM., editors. Cytokine Storm Syndrome. Cham: Springer International Publishing; 2024. pp. 9–19.
14.
JankaGE, AricòM. Clinical features, diagnosis and therapy of familial haemophagocytic lymphohistiocytosis. Acta Paediatr2021;110(10):2723–2728.
15.
Al-SamkariH, BerlinerN. Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol2018;13(1):27–49.
BrisseE, WoutersCH, MatthysP. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: Differences and similarities. Br J Haematol2016;174(2):203–217.
18.
BöhmS, WustrauK, Pachlopnik SchmidJ, et al.Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: Etoposide is better than its reputation. Blood2024;143(10):872–881.
19.
CarmoM, RismaKA, ArumugamP, et al.Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency. Mol Ther2015;23(4):737–745.
20.
TiwariS, HontzA, TerrellCE, et al.High level of perforin expression is required for effective correction of hemophagocytic lymphohistiocytosis. Hum Gene Ther2016;27(10):847–859.
21.
SoheiliT, RivièreJ, RicciardelliI, et al.Gene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice. Blood2016;128(24):2859–2862.
22.
SoheiliT, DurandA, SepulvedaFE, et al.Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency. Blood Adv2017;1(27):2781–2789.
23.
GhoshS, CarmoM, Calero-GarciaM, et al.T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations. J Allergy Clin Immunol2018;142(3):904–913.e3.
24.
DettmerV, BloomK, GrossM, et al.Retroviral UNC13D gene transfer restores cytotoxic activity of T cells derived from familial hemophagocytic lymphohistiocytosis type 3 patients in vitro. Hum Gene Ther2019;30(8):975–984.
25.
TakushiSE, PaikNY, FedanovA, et al.Lentiviral gene therapy for familial hemophagocytic lymphohistiocytosis type 3, caused by UNC13D genetic defects. Hum Gene Ther2020;31(11–12):626–638.
26.
Dettmer-MonacoV, WeißertK, AmmannS, et al.Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol2024;153(1):243–255.e14.
27.
LiX, WirtzT, WeberT, et al.Precise CRISPR-Cas9 gene repair in autologous memory T cells to treat familial hemophagocytic lymphohistiocytosis. Sci Immunol2024;9(92):eadi0042.
28.
LeiL, KaufmannMM, LaoJ, et al.Genotoxicity profiling reveals distinct platform- and cell type–specific effects in therapeutic gene editing for genetic hyperinflammation. Cell Stem Cell2026;33(6):930–944.e5; doi: 10.1016/j.stem.2026.04.014
29.
TopalJ, PanchalN, BarroetaA, et al.Lentiviral gene transfer corrects immune abnormalities in XIAP deficiency. J Clin Immunol2023;43(2):440–451.
30.
PanchalN, GhoshS, BoothC. T cell gene therapy to treat immunodeficiency. Br J Haematol2021;192(3):433–443.
31.
TuerxunyimingM, YinJM, ZhuP, et al.A targeting lentiviral vector for generation of CAR-T cells in vivo. Sci Rep2026;16(1):9566.
32.
CowanMJ, YuJ, FacchinoJ, et al.Lentiviral gene therapy for artemis-deficient SCID. N Engl J Med2022;387(25):2344–2355.
33.
WuG, LiuS, HagensteinJ, et al.Adeno-associated virus-based gene therapy treats inflammatory kidney disease in mice. J Clin Invest2024;134(17):e174722.
34.
CetinB, ErendorF, EksiYE, et al.Gene and cell therapy of human genetic diseases: Recent advances and future directions. J Cell Mol Med2024;28(17):e70056.
35.
Lagresle-PeyrouC, DianaJ-S, MagrinE, et al.Preclinical assessment for gene addition strategy in familial hemophagocytic lymphohistiocytosis related to Munc 13-4 deficiency. Blood2023;142(Supplement 1):3633.
36.
A Phase I/II open label non randomized study, monocentric, single arm, evaluating safety and efficacy of gene therapy of FHL 3 caused by mutations in the human UNC13D gene by transplantation of a single dose of autologous CD34+ Cells transduced ex vivo with the UNC13D LV vector expressing the UNC13D CDNA [Internet]. 2024. Available from: https://clinicaltrials.gov/study/NCT06736080 [Last accessed: May27, 2026].
37.
MeyerLK, LeeJC, RoccoJM, et al.Histiocyte Society blueprint for hemophagocytic lymphohistiocytosis research: Deciphering underlying disease mechanisms to optimize diagnosis and therapy. Haematologica2025;110(11):2572–2587.
38.
SteenEA, NicholsKE, MeyerLK. Insights into the cellular pathophysiology of familial hemophagocytic lymphohistiocytosis. Front Immunol2023;14:1147603.
39.
WeißertK, AmmannS, KöglT, et al.Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH). EMBO Mol Med2022;14(12):e16085.
40.
TerrellCE, JordanMB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8+ T cells and dendritic cells. Blood2013;121(26):5184–5191.
41.
TerrellCE, JordanMB. Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood2013;122(15):2618–2621.
42.
JordanM, CarmoM, TiwariS, et al.Gene therapy for hemophagocytic lymphohistiocytosis (HLH): Fixing a criticial ‘Circuit Breaker’ in the immune system. Blood2012;120(21):3158.
43.
VicenteMM, Chaves-FerreiraM, JorgeJMP, et al.The off-targets of clustered regularly interspaced short palindromic repeats gene editing. Front Cell Dev Biol2021;9:718466.
44.
DodsworthBT, HatjeK, MeyerCA, et al.Rates of homology directed repair of CRISPR-Cas9 induced double strand breaks are lower in naïve compared to primed human pluripotent stem cells. Stem Cell Res2020;46(1):101852.
45.
FerrariS, VavassoriV, CanaruttoD, et al.Gene editing of hematopoietic stem cells: Hopes and hurdles toward clinical translation. Front Genome Ed2021;3:618378.
46.
ShinJJ, SchröderMS, CaiadoF, et al.Controlled cycling and quiescence enables efficient HDR in engraftment-enriched adult hematopoietic stem and progenitor cells. Cell Rep2020;32(9):108093.
47.
ZarghamianP, KlermundJ, CathomenT. Clinical genome editing to treat sickle cell disease-A brief update. Front Med (Lausanne)2022;9:1065377.
48.
FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med2021;384(3):252–260.
49.
FrangoulH, LocatelliF, SharmaA, et al.; CLIMB SCD-121 Study Group. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med2024;390(18):1649–1662.
50.
LocatelliF, LangP, WallD, et al.; CLIMB THAL-111 Study Group. Exagamglogene autotemcel for transfusion-dependent β-thalassemia. N Engl J Med2024;390(18):1663–1676.
51.
FrangoulH, HannaR, WaltersMC, et al.; EdiThal Investigators. CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat β-thalassemia. N Engl J Med2026;394(13):1292–1301.
52.
HannaR, FrangoulH, PineiroL, et al.; RUBY Investigators. CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat sickle cell disease. N Engl J Med2026;394(13):1281–1291.
53.
GuptaAO, SharmaA, FrangoulH, et al.; BEACON Investigators. Base editing of HBG1 and HBG2 promoters for sickle cell disease. N Engl J Med2026;394(18):1824–1835.
HartzB, MarshR, RaoK, et al.The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood2016;127(25):3281–3290.
56.
WegehauptO, WustrauK, LehmbergK, et al.Cell versus cytokine–directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity. Front Immunol2020;11:808.
57.
AiutiA, RoncaroloMG, NaldiniL. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: Paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med2017;9(6):737–740.
58.
BraunCJ, WitzelM, ParuzynskiA, et al.Gene therapy for Wiskott-Aldrich Syndrome-Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis. Rare Dis2014;2(1):e947749.
59.
OttMG, SchmidtM, SchwarzwaelderK, et al.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med2006;12(4):401–409.
60.
KangEM, ChoiU, TheobaldN, et al.Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood2010;115(4):783–791.
61.
De RavinSS, LiL, WuX, et al.CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci Transl Med2017;9(372):eaah3480.
62.
CeticaV, PendeD, GriffithsGM, et al.Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica2010;95(4):538–541.
63.
CichockiF, SchlumsH, LiH, et al.Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. J Exp Med2014;211(6):1079–1091.
64.
SantoroA, CannellaS, TrizzinoA, et al.Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3. Haematologica2008;93(7):1086–1090.
65.
SchulertGS, ZhangM, HusamiA, et al.Brief report: Novel UNC13D intronic variant disrupting an NF-κB enhancer in a patient with recurrent macrophage activation syndrome and systemic juvenile idiopathic arthritis. Arthritis Rheumatol2018;70(6):963–970.
66.
GalganoD, SoheiliT, VossM, et al.Alternative UNC13D promoter encodes a functional Munc13-4 isoform predominantly expressed in lymphocytes and platelets. Front Immunol2020;11:1154.
67.
MeethsM, ChiangSCC, WoodSM, et al.Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood2011;118(22):5783–5793.
68.
SieniE, CeticaV, SantoroA, et al.Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet2011;48(5):343–352.
69.
WillenbringRC, IkedaY, PeaseLR, et al.Human perforin gene variation is geographically distributed. Mol Genet Genomic Med2018;6(1):44–55.
70.
TrapaniJA, VoskoboinikI. Perforinopathy: A spectrum of human immune disease caused by defective perforin delivery or function. Front Immunol2013;4:441.
71.
PavaniG, AmendolaM. Targeted gene delivery: Where to land. Front Genome Ed2020;2:609650.
72.
AllenAG, KhanSQ, MarguliesCM, et al.A highly efficient transgene knock-in technology in clinically relevant cell types. Nat Biotechnol2024;42(3):458–469.
73.
YeoJH, KimHH, OhSH, et al.Highly efficient and scarless genome editing via essential gene-coupled homology-directed repair. Genome Res2026;36(6):1187–1198.
74.
HaiderS, MussolinoC. Fine-tuning homology-directed repair (HDR) for precision genome editing: Current strategies and future directions. Int J Mol Sci2025;26(9):4067.
75.
KosickiM, TombergK, BradleyA. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol2018;36(8):765–771.
76.
BlattnerG, CavazzaA, ThrasherAJ, et al.Gene editing and genotoxicity: Targeting the off-targets. Front Genome Ed2020;2:613252.
77.
LiuM, ZhangW, XinC, et al.Global detection of DNA repair outcomes induced by CRISPR–Cas9. Nucleic Acids Res2021;49(15):8732–8742.
78.
HwangG-H, LeeS-H, OhM, et al.Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleases. Nat Biomed Eng2025;9(1):79–92.
ReganSB, MedhiD, XuY, et al.Megabase-scale loss of heterozygosity provoked by CRISPR-Cas9 DNA double-strand breaks. Mol Cell2025;85(22):4119–4137. e10.
81.
AusselC, CathomenT, Fuster-GarcíaC. The hidden risks of CRISPR/Cas: Structural variations and genome integrity. Nat Commun2025;16(1):7208.
82.
Hacein-Bey-AbinaS, GarrigueA, WangGP, et al.Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest2008;118(9):3132–3142.
83.
BraunCJ, BoztugK, ParuzynskiA, et al.Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med2014;6(227):227ra33.
84.
MusunuruK, GrandinetteSA, WangX, et al.Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med2025;392(22):2235–2243.
85.
GoriJL, HaddadE, FrangoulH, et al.Prime editing for p47(phox)-deficient chronic granulomatous disease. N Engl J Med2026;394(12):1195–1203.
86.
LiC, GeorgakopoulouA, NewbyGA, et al.In vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood2023;141(17):2085–2099.
87.
BöckD, RothganglT, VilligerL, et al.In vivo prime editing of a metabolic liver disease in mice. Sci Transl Med2022;14(636):eabl9238.
88.
AnzaloneAV, GaoXD, PodrackyCJ, et al.Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat Biotechnol2022;40(5):731–740.
89.
AnzaloneAV, RandolphPB, DavisJR, et al.Search-and-replace genome editing without double-strand breaks or donor DNA. Nature2019;576(7785):149–157.
90.
ShiY-J, DingZ-Y, WuY, et al.Quadruple pegRNA enables programmable and efficient large genomic insertion. Nature2026;654(8117):272–281.
91.
BergstenE, HorneA, Hed MyrbergI, et al.Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: Results from the HLH-2004 study. Blood Adv2020;4(15):3754–3766.
92.
CharlesworthCT, HsuI, WilkinsonAC, et al.Immunological barriers to haematopoietic stem cell gene therapy. Nat Rev Immunol2022;22(12):719–733.
93.
AllenCE, MarshR, DawsonP, et al.Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood2018;132(13):1438–1451.
94.
MurrayJ, EinhausT, RadtkeS, et al.Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates. Blood Adv2026;10(4):1094–1105.
95.
CasiratiG, CosentinoA, MucciA, et al.Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature2023;621(7978):404–414.
96.
MaroneR, LeporeR, RositzkaJ, et al.Function-preserving single amino acid substitutions shield hematopoietic stem and progenitor cells from CD117 targeted immunotherapy in vivo. Blood2022;140(Supplement 1):4493–4494.
97.
MaroneR, LandmannE, DevauxA, et al.Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy. J Exp Med2023;220(12):e20231235.
98.
SobrinoS, JosephL, MagrinE, et al.Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease. Nat Commun2025;16(1):3137.
HussmannJA, LingJ, RavisankarP, et al.Mapping the genetic landscape of DNA double-strand break repair. Cell2021;184(22):5653–5669.e25.
101.
FerrariG, ThrasherAJ, AiutiA. Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet2021;22(4):216–234.
102.
FoxTA, HoughtonBC, BoothC. Gene edited T cell therapies for inborn errors of immunity. Front Genome Ed2022;4:899294.
103.
MasarwyR, Stotsky-OterinL, ElishaA, et al.Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications. Adv Drug Deliv Rev2024;211(8):115359.
104.
VavassoriV, FerrariS, BerettaS, et al.Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. Blood2023;142(9):812–826.
105.
BredaL, PappTE, TriebwasserMP, et al.In vivo hematopoietic stem cell modification by mRNA delivery. Science2023;381(6656):436–443.
106.
HaldrupJ, AndersenS, LabialARL, et al.Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Res2023;51(18):10059–10074.
107.
MangeotPE, RissonV, FusilF, et al.Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat Commun2019;10(1):45.
108.
NielsenIH, RovsingAB, JannsJH, et al.Cell-targeted gene modification by delivery of CRISPR-Cas9 ribonucleoprotein complexes in pseudotyped lentivirus-derived nanoparticles. Mol Ther Nucleic Acids2024;35(4):102318.
109.
CharlesworthCT, HommaS, AmayaAK, et al.Highly efficient in vivo hematopoietic stem cell transduction using an optimized self-complementary adeno-associated virus. Mol Ther Methods Clin Dev2025;33(1):101438.
110.
WilkinsonAC, DeverDP, BaikR, et al.Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat Commun2021;12(1):686.
111.
KurshakovaEV, LevchenkoOA, SmirnikhinaSA, et al.The promise and pitfalls of AAV-mediated gene therapy for duchenne muscular dystrophy. Curr Issues Mol Biol2025;47(12):1058.
112.
CaoR, ThatavartyA, KingKY. Forged in the fire: Lasting impacts of inflammation on hematopoietic progenitors. Exp Hematol2024;134(6):104215.
